Therapeutic effect of the regiment of helicobacter pylori treatment on the improvement of pain and symptoms of arthritis in patients with rheumatoid arthritis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231209060313N1

Enrollment

Registered

2024-01-10

Start date

2024-01-27

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis. Rheumatoid arthritis with rheumatoid factor

Interventions

Intervention 1: Intervention group: patients with rheumatoid arthritis whose presence of Helicobacter pylori has been proven by endoscopy or stool test or positive Helicobacter pylori serology test. I

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years Patients with mild to moderate rheumatoid arthritis diagnosed by EULAR criteria (under traditional treatment with DMARD) Willingness to participate in the clinical trial Presence of positive H pylori infection based on endoscopy, fecal antigen or serum antibody test No recent use of antibiotics Absence of immunodeficiency diseases and active cancer Having an indication for the treatment of Helicobacter pylori infection

Exclusion criteria

Exclusion criteria: The patient's unwillingness to participate in the clinical trial death of the patient Severe rheumatoid arthritis and the use of biological drugs in the treatment of RA Patients with other systemic diseases, who have gastrointestinal surgery, have an active gastric ulcer, or synovectomy in any major joint. pregnancy

Design outcomes

Primary

Measure	Time frame
Severity of pain. Timepoint: Measurement of pain severity before the intervention and 4 and 8 weeks after the intervention. Method of measurement: Visual Analogue Scale (VAS) Questionnaire.;Disease activity. Timepoint: Measurement of Disease activity before the intervention and 4 and 8 weeks after the intervention. Method of measurement: DAS-28 Questionnaire.;Tender joints. Timepoint: Measurement of Tender joints before the intervention and 4 and 8 weeks after the intervention. Method of measurement: DAS-28 Questionnaire.;Swollen joints. Timepoint: Measurement of swollen joints before the intervention and 4 and 8 weeks after the intervention. Method of measurement: DAS-28 Questionnaire.;Morning stiffness. Timepoint: Measurement of morning stifness before the intervention and 4 and 8 weeks after the intervention. Method of measurement: DAS-28 Questionnaire.;Serum level of C-reactive protein. Timepoint: Measurement of Serum level of C-reactive protein before the intervention and 4 and 8 weeks after the intervention. Method of measurement: Measurement Serum level of C-reactive protein with a Flame Photometer.;Serum level of ESR. Timepoint: Measurement of Serum level of ESR before the intervention and 4 and 8 weeks after the intervention. Method of measurement: Measurement of serum ESR level with a Flame Photometer.;Quality of life. Timepoint: Measuring different aspects of quality of life before the intervention and 4 and 8 weeks after the intervention. Method of measurement: HAQ , EQ-5D Questionnaire.	—

Measure

Time frame

Severity of pain. Timepoint: Measurement of pain severity before the intervention and 4 and 8 weeks after the intervention. Method of measurement: Visual Analogue Scale (VAS) Questionnaire.;Disease activity. Timepoint: Measurement of Disease activity before the intervention and 4 and 8 weeks after the intervention. Method of measurement: DAS-28 Questionnaire.;Tender joints. Timepoint: Measurement of Tender joints before the intervention and 4 and 8 weeks after the intervention. Method of measurement: DAS-28 Questionnaire.;Swollen joints. Timepoint: Measurement of swollen joints before the intervention and 4 and 8 weeks after the intervention. Method of measurement: DAS-28 Questionnaire.;Morning stiffness. Timepoint: Measurement of morning stifness before the intervention and 4 and 8 weeks after the intervention. Method of measurement: DAS-28 Questionnaire.;Serum level of C-reactive protein. Timepoint: Measurement of Serum level of C-reactive protein before the intervention and 4 and 8 weeks after the intervention. Method of measurement: Measurement Serum level of C-reactive protein with a Flame Photometer.;Serum level of ESR. Timepoint: Measurement of Serum level of ESR before the intervention and 4 and 8 weeks after the intervention. Method of measurement: Measurement of serum ESR level with a Flame Photometer.;Quality of life. Timepoint: Measuring different aspects of quality of life before the intervention and 4 and 8 weeks after the intervention. Method of measurement: HAQ , EQ-5D Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactArdalan Memar

Shahre-kord University of Medical Sciences

ardalanmemar@yahoo.com+98 38 3222 0016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026